Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466683 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
A Phase 2 study of COVID-19 and Pneumonia, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 7
- Study locations
NCT04466683 is a Phase 2 study of COVID-19 and Pneumonia that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 37 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT04466683, a Phase 2 study of COVID-19 and Pneumonia, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 7
- Study locations
Study Summary
Low doses of radiation in the form of chest x-rays has been in the past to treat people with pneumonia. This treatment was thought to reduce inflammation and was found to be effective without side effects. However, it was an expensive treatment and was eventually replaced with less expensive treatment options like penicillin. The COVID-19 virus has emerged recently, causing high rates of pneumonia in people. The authors believe that giving a small dose of radiation to the lungs may reduce inflammation and neutralize the pneumonia caused by COVID-19. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers. The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from COVID-19 infection, which could reduce the need for a ventilator or breathing tube.
Interventions
- RADIATION Low dose radiation 35 cGy
- RADIATION High dose radiation 100 cGy
Study Locations (7)
Florida
- Boca Raton Regional Hospital Lynn Cancer Institute - Boca Raton
- Miami Cancer Institute - Miami
Illinois
- Loyola University Chicago - Maywood
Indiana
- Indiana University School of Medicine - Indianapolis
Massachusetts
- Lowell General Hospital Cancer Center - Lowell
Ohio
- Ohio State University James Cancer Hospital - Columbus
Other
- Hospital Universitario San Ignacio - Bogotá
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04466683
The ClinicalTrials.gov registry entry for NCT04466683 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Low dose radiation 35 cGy is the first listed.
NCT04466683 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Florida, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT04466683 about?
NCT04466683 is a clinical study titled "Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia". Low doses of radiation in the form of chest x-rays has been in the past to treat people with pneumonia. This treatment was thought to reduce inflammation and was found to be effective without side effects. However, it was an expensive treatment and was eventually replaced with less expensive treatme...
What is the current status of trial NCT04466683?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2020-08-28. Estimated completion is 2025-12-31.
What conditions does trial NCT04466683 study?
This clinical trial studies the following conditions: COVID-19, Pneumonia, Sars-CoV2.
What interventions are being tested in trial NCT04466683?
The interventions under investigation include: Low dose radiation 35 cGy (RADIATION), High dose radiation 100 cGy (RADIATION).
Who is sponsoring clinical trial NCT04466683?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04466683 being conducted?
This trial has 7 study locations across Florida, Illinois, Indiana, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.